Oric Pharmaceuticals (NASDAQ:ORIC) Earns Buy Rating from BTIG Research

Oric Pharmaceuticals logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • BTIG Research reiterated its Buy rating on Oric Pharmaceuticals and set a $26 price target, implying potential upside of 245.74% from the stock’s current price.
  • Analyst views are mostly positive: 14 rate the stock Buy, one Hold and one Sell, producing a consensus “Moderate Buy” rating and an average target of $21.25.
  • Oric reported a quarterly loss of $0.44 per share, missing analyst expectations of a $0.39 loss. The CFO also sold 77,000 shares in August under a pre-arranged trading plan.
  • Five stocks to consider instead of Oric Pharmaceuticals.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at BTIG Research in a research report issued on Tuesday, Benzinga reports. They currently have a $26.00 price objective on the stock. BTIG Research's price objective would suggest a potential upside of 245.74% from the company's current price.

A number of other research analysts have also recently issued reports on ORIC. Stifel Nicolaus boosted their price objective on shares of Oric Pharmaceuticals from $14.00 to $18.00 and gave the company a "buy" rating in a report on Monday, October 26th. Wedbush cut their target price on shares of Oric Pharmaceuticals from $17.00 to $14.00 and set an "outperform" rating on the stock in a report on Tuesday, October 27th. Weiss Ratings reissued a "sell (d-)" rating on shares of Oric Pharmaceuticals in a research report on Thursday, October 15th. Wall Street Zen raised shares of Oric Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday, July 25th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Oric Pharmaceuticals from $23.00 to $26.00 and gave the company an "overweight" rating in a report on Wednesday, October 14th. Fourteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Oric Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $21.25.

Check Out Our Latest Stock Report on ORIC

Oric Pharmaceuticals Stock Performance

Oric Pharmaceuticals stock opened at $7.52 on Tuesday. The business has a 50-day moving average of $11.45 and a 200-day moving average of $10.99. Oric Pharmaceuticals has a 1 year low of $7.23 and a 1 year high of $14.68.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last announced its quarterly earnings results on Monday, November 16th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.05). On average, analysts anticipate that Oric Pharmaceuticals will post -1.53 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Dominic Piscitelli sold 77,000 shares of the stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $13.69, for a total transaction of $1,054,130.00. Following the completion of the sale, the chief financial officer directly owned 69,828 shares of the company's stock, valued at approximately $955,945.32. This represents a 52.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 105,000 shares of company stock valued at $1,432,952. 5.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. bought a new stake in Oric Pharmaceuticals in the 2nd quarter valued at $73,904,000. Siren L.L.C. increased its holdings in Oric Pharmaceuticals by 197.6% during the 1st quarter. Siren L.L.C. now owns 2,998,192 shares of the company's stock worth $37,987,000 after purchasing an additional 1,990,617 shares in the last quarter. Algert Global LLC increased its holdings in Oric Pharmaceuticals by 791.3% during the 2nd quarter. Algert Global LLC now owns 1,215,293 shares of the company's stock worth $13,162,000 after purchasing an additional 1,078,943 shares in the last quarter. Bank of America Corp DE bought a new position in Oric Pharmaceuticals during the 2nd quarter worth about $11,675,000. Finally, Defilade Capital Management L.P. acquired a new stake in shares of Oric Pharmaceuticals in the 1st quarter valued at about $10,680,000. Institutional investors own 95.05% of the company's stock.

About Oric Pharmaceuticals

(Get Free Report)

Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its research centers on therapies intended to address treatment resistance and improve outcomes for people with tumors that have become difficult to treat. The company's drug candidates have included ORIC-114, a targeted therapy designed to inhibit EGFR and HER2 alterations, and ORIC-944, which targets the PRC2 pathway and has been investigated for prostate cancer. These programs are investigational and are not approved medicines.

Featured Articles

Analyst Recommendations for Oric Pharmaceuticals (NASDAQ:ORIC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Oric Pharmaceuticals Right Now?

Before you consider Oric Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oric Pharmaceuticals wasn't on the list.

While Oric Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines